Characteristics and indications of oxcarbazepine
To review the major studies published concerning the pharmacokinetic characteristics, mechanism of action, clinical efficacy and adverse effects of oxcarbazepine (OXC). OXC is a ketoderivative of carbamazepine (CBZ), with a similar mechanism of action, possibly widening the voltage dependent potassi...
Gespeichert in:
| Veröffentlicht in: | Revista de neurologiá 2002-09, Vol.35 Suppl 1, p.S101 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | spa |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | S101 |
| container_title | Revista de neurologiá |
| container_volume | 35 Suppl 1 |
| creator | Herranz, J L Argumosa, A |
| description | To review the major studies published concerning the pharmacokinetic characteristics, mechanism of action, clinical efficacy and adverse effects of oxcarbazepine (OXC).
OXC is a ketoderivative of carbamazepine (CBZ), with a similar mechanism of action, possibly widening the voltage dependent potassium channels. Its pharmacokinetic characteristics are much better than those CBZ but the frequency and intensity of interactions is much less. In several double blind trials, using the drug in monotherapy in previously untreated patients, similar efficacy was found after OXC, phenytoin, valproate and CBZ but the fewest adverse effects were seen after OXC.
OXC is an antiepileptic drug with better pharmacokinetic properties than CBZ and similar clinical efficacy, but better tolerated, so it may therefore be expected to replace this classical antiepileptic drug for use in monotherapy and polytherapy of both children and adults in all types of partial seizures. |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_12373662</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>12373662</sourcerecordid><originalsourceid>FETCH-LOGICAL-g164t-cde5f82df12a38935909cc7da31550b6e7b7e34f9750fffffa4b6b7dbddad0133</originalsourceid><addsrcrecordid>eNo1jstKBDEQAHNQ3HX1F2R-YKCTzmNzlMEXLOxFz0snnWjEnRmSEdSvF1HrUreiTsQalIQeQMJKnLf2CqBRezgTK6nQobVqLWB4oUpxSbW0pcTW0chdGblEWso0tm7K3fQRqQb6SnMZ04U4zfTW0uWfN-Lp9uZxuO93-7uH4XrXP0urlz5yMnmrOEtFuPVoPPgYHRNKYyDY5IJLqLN3BvIPpIMNjgMzMUjEjbj67c7v4Zj4MNdypPp5-F_Hb-0VP7k</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Characteristics and indications of oxcarbazepine</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Herranz, J L ; Argumosa, A</creator><creatorcontrib>Herranz, J L ; Argumosa, A</creatorcontrib><description>To review the major studies published concerning the pharmacokinetic characteristics, mechanism of action, clinical efficacy and adverse effects of oxcarbazepine (OXC).
OXC is a ketoderivative of carbamazepine (CBZ), with a similar mechanism of action, possibly widening the voltage dependent potassium channels. Its pharmacokinetic characteristics are much better than those CBZ but the frequency and intensity of interactions is much less. In several double blind trials, using the drug in monotherapy in previously untreated patients, similar efficacy was found after OXC, phenytoin, valproate and CBZ but the fewest adverse effects were seen after OXC.
OXC is an antiepileptic drug with better pharmacokinetic properties than CBZ and similar clinical efficacy, but better tolerated, so it may therefore be expected to replace this classical antiepileptic drug for use in monotherapy and polytherapy of both children and adults in all types of partial seizures.</description><identifier>ISSN: 0210-0010</identifier><identifier>PMID: 12373662</identifier><language>spa</language><publisher>Spain</publisher><subject>Animals ; Anticonvulsants - adverse effects ; Anticonvulsants - pharmacokinetics ; Anticonvulsants - therapeutic use ; Carbamazepine - adverse effects ; Carbamazepine - analogs & derivatives ; Carbamazepine - pharmacokinetics ; Carbamazepine - therapeutic use ; Clinical Trials as Topic ; Disease Models, Animal ; Dose-Response Relationship, Drug ; Drug Interactions ; Epilepsy - drug therapy ; Humans ; Ion Channels - metabolism ; Molecular Structure ; Placebos ; Treatment Outcome</subject><ispartof>Revista de neurologiá, 2002-09, Vol.35 Suppl 1, p.S101</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12373662$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Herranz, J L</creatorcontrib><creatorcontrib>Argumosa, A</creatorcontrib><title>Characteristics and indications of oxcarbazepine</title><title>Revista de neurologiá</title><addtitle>Rev Neurol</addtitle><description>To review the major studies published concerning the pharmacokinetic characteristics, mechanism of action, clinical efficacy and adverse effects of oxcarbazepine (OXC).
OXC is a ketoderivative of carbamazepine (CBZ), with a similar mechanism of action, possibly widening the voltage dependent potassium channels. Its pharmacokinetic characteristics are much better than those CBZ but the frequency and intensity of interactions is much less. In several double blind trials, using the drug in monotherapy in previously untreated patients, similar efficacy was found after OXC, phenytoin, valproate and CBZ but the fewest adverse effects were seen after OXC.
OXC is an antiepileptic drug with better pharmacokinetic properties than CBZ and similar clinical efficacy, but better tolerated, so it may therefore be expected to replace this classical antiepileptic drug for use in monotherapy and polytherapy of both children and adults in all types of partial seizures.</description><subject>Animals</subject><subject>Anticonvulsants - adverse effects</subject><subject>Anticonvulsants - pharmacokinetics</subject><subject>Anticonvulsants - therapeutic use</subject><subject>Carbamazepine - adverse effects</subject><subject>Carbamazepine - analogs & derivatives</subject><subject>Carbamazepine - pharmacokinetics</subject><subject>Carbamazepine - therapeutic use</subject><subject>Clinical Trials as Topic</subject><subject>Disease Models, Animal</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Interactions</subject><subject>Epilepsy - drug therapy</subject><subject>Humans</subject><subject>Ion Channels - metabolism</subject><subject>Molecular Structure</subject><subject>Placebos</subject><subject>Treatment Outcome</subject><issn>0210-0010</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1jstKBDEQAHNQ3HX1F2R-YKCTzmNzlMEXLOxFz0snnWjEnRmSEdSvF1HrUreiTsQalIQeQMJKnLf2CqBRezgTK6nQobVqLWB4oUpxSbW0pcTW0chdGblEWso0tm7K3fQRqQb6SnMZ04U4zfTW0uWfN-Lp9uZxuO93-7uH4XrXP0urlz5yMnmrOEtFuPVoPPgYHRNKYyDY5IJLqLN3BvIPpIMNjgMzMUjEjbj67c7v4Zj4MNdypPp5-F_Hb-0VP7k</recordid><startdate>20020901</startdate><enddate>20020901</enddate><creator>Herranz, J L</creator><creator>Argumosa, A</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>20020901</creationdate><title>Characteristics and indications of oxcarbazepine</title><author>Herranz, J L ; Argumosa, A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g164t-cde5f82df12a38935909cc7da31550b6e7b7e34f9750fffffa4b6b7dbddad0133</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>spa</language><creationdate>2002</creationdate><topic>Animals</topic><topic>Anticonvulsants - adverse effects</topic><topic>Anticonvulsants - pharmacokinetics</topic><topic>Anticonvulsants - therapeutic use</topic><topic>Carbamazepine - adverse effects</topic><topic>Carbamazepine - analogs & derivatives</topic><topic>Carbamazepine - pharmacokinetics</topic><topic>Carbamazepine - therapeutic use</topic><topic>Clinical Trials as Topic</topic><topic>Disease Models, Animal</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Interactions</topic><topic>Epilepsy - drug therapy</topic><topic>Humans</topic><topic>Ion Channels - metabolism</topic><topic>Molecular Structure</topic><topic>Placebos</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Herranz, J L</creatorcontrib><creatorcontrib>Argumosa, A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Revista de neurologiá</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Herranz, J L</au><au>Argumosa, A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Characteristics and indications of oxcarbazepine</atitle><jtitle>Revista de neurologiá</jtitle><addtitle>Rev Neurol</addtitle><date>2002-09-01</date><risdate>2002</risdate><volume>35 Suppl 1</volume><spage>S101</spage><pages>S101-</pages><issn>0210-0010</issn><abstract>To review the major studies published concerning the pharmacokinetic characteristics, mechanism of action, clinical efficacy and adverse effects of oxcarbazepine (OXC).
OXC is a ketoderivative of carbamazepine (CBZ), with a similar mechanism of action, possibly widening the voltage dependent potassium channels. Its pharmacokinetic characteristics are much better than those CBZ but the frequency and intensity of interactions is much less. In several double blind trials, using the drug in monotherapy in previously untreated patients, similar efficacy was found after OXC, phenytoin, valproate and CBZ but the fewest adverse effects were seen after OXC.
OXC is an antiepileptic drug with better pharmacokinetic properties than CBZ and similar clinical efficacy, but better tolerated, so it may therefore be expected to replace this classical antiepileptic drug for use in monotherapy and polytherapy of both children and adults in all types of partial seizures.</abstract><cop>Spain</cop><pmid>12373662</pmid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0210-0010 |
| ispartof | Revista de neurologiá, 2002-09, Vol.35 Suppl 1, p.S101 |
| issn | 0210-0010 |
| language | spa |
| recordid | cdi_pubmed_primary_12373662 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Animals Anticonvulsants - adverse effects Anticonvulsants - pharmacokinetics Anticonvulsants - therapeutic use Carbamazepine - adverse effects Carbamazepine - analogs & derivatives Carbamazepine - pharmacokinetics Carbamazepine - therapeutic use Clinical Trials as Topic Disease Models, Animal Dose-Response Relationship, Drug Drug Interactions Epilepsy - drug therapy Humans Ion Channels - metabolism Molecular Structure Placebos Treatment Outcome |
| title | Characteristics and indications of oxcarbazepine |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T22%3A46%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Characteristics%20and%20indications%20of%20oxcarbazepine&rft.jtitle=Revista%20de%20neurologi%C3%A1&rft.au=Herranz,%20J%20L&rft.date=2002-09-01&rft.volume=35%20Suppl%201&rft.spage=S101&rft.pages=S101-&rft.issn=0210-0010&rft_id=info:doi/&rft_dat=%3Cpubmed%3E12373662%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/12373662&rfr_iscdi=true |